Stock listing

NSE:MANKIND Mankind Pharma Ltd. Share Price

Home listing (NSE) of Mankind Pharma Ltd.

Follow Mankind Pharma Ltd. into a list and get an email when it puts out news.

Share price · NSE:MANKIND

₹2,665.00 INR +40.00 (+1.5%)

Close on Nov 20, 2026

Past year +19.0% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
₹2,620.20 – ₹2,669.90 INRNov 20, 2026
Volume
455,810 sharesNov 20, 2026
Market cap
₹1.10T INRAt the close on Nov 20, 2026 · price × 413.0M shares outstanding
52-week range
₹1,909.70 – ₹2,705.00 INRLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
₹1.36B INRMedian day 427,448 shares · 2 days with no trades · last 3 months, Aug 20, 2026 – Nov 20, 2026
Mankind Pharma Ltd. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NSE:MANKIND · Home₹2,665.00 INR+40.00 (+1.5%)455,810₹2,627.00₹2,669.90₹2,620.20₹2,625.00Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NSE:MANKIND · INR, adjusted for splits

DayCloseChange%OpenHighLowVolume
₹2,665.00+40.00+1.5%₹2,627.00₹2,669.90₹2,620.20455,810
₹2,625.00+15.00+0.6%₹2,619.90₹2,645.50₹2,607.10341,826
₹2,610.00-16.60-0.6%₹2,628.30₹2,640.00₹2,610.00324,555
₹2,626.60-13.40-0.5%₹2,625.60₹2,694.00₹2,612.20426,990
₹2,640.00+1.40+0.1%₹2,638.60₹2,676.00₹2,627.80494,716
₹2,638.60-21.40-0.8%₹2,660.00₹2,667.90₹2,631.20424,048
₹2,660.00-8.30-0.3%₹2,682.00₹2,695.60₹2,630.80844,460
₹2,668.30+128.30+5.1%₹2,600.00₹2,705.00₹2,585.201,515,775
₹2,540.00+22.00+0.9%₹2,508.00₹2,545.00₹2,489.00274,415
₹2,518.00-19.90-0.8%₹2,560.00₹2,561.20₹2,495.00377,284
₹2,537.90+62.90+2.5%₹2,485.00₹2,540.00₹2,476.00655,415
₹2,475.00-6.20-0.2%₹2,500.00₹2,500.00₹2,461.10770,945
₹2,481.20-11.60-0.5%₹2,505.30₹2,512.30₹2,457.90448,003
₹2,492.80+23.50+1.0%₹2,469.30₹2,528.00₹2,467.40681,380
₹2,469.30-20.70-0.8%₹2,490.00₹2,509.00₹2,457.50728,515
₹2,490.00-12.50-0.5%₹2,496.60₹2,549.00₹2,477.401,085,402
₹2,502.50+190.50+8.2%₹2,358.50₹2,529.80₹2,352.103,030,527
₹2,312.00+99.40+4.5%₹2,223.70₹2,333.90₹2,215.001,024,537
₹2,212.60-63.00-2.8%₹2,282.90₹2,289.60₹2,196.10679,100
₹2,275.60-9.90-0.4%₹2,266.00₹2,299.60₹2,233.60649,740
₹2,285.50+32.30+1.4%₹2,256.20₹2,285.50₹2,243.10246,631
₹2,253.20-22.30-1.0%₹2,264.10₹2,348.50₹2,246.001,228,705
₹2,275.50-72.10-3.1%₹2,349.90₹2,354.40₹2,268.70889,731
₹2,347.60+12.60+0.5%₹2,325.60₹2,365.00₹2,321.10645,492
₹2,335.00-37.00-1.6%₹2,372.00₹2,372.00₹2,317.50498,158
₹2,372.00-28.00-1.2%₹2,400.00₹2,401.10₹2,356.20329,114
₹2,400.00+31.50+1.3%₹2,368.50₹2,426.80₹2,368.50205,896
₹2,368.50-11.50-0.5%₹2,380.00₹2,389.80₹2,342.00306,899
₹2,380.00-120.00-4.8%₹2,501.10₹2,510.90₹2,347.60783,247
₹2,500.000.000.0%₹2,500.90₹2,530.00₹2,480.10242,210
₹2,500.00+21.00+0.8%₹2,481.00₹2,508.90₹2,464.50297,524
₹2,479.00-56.00-2.2%₹2,533.10₹2,539.30₹2,464.70527,032
₹2,535.000.000.0%₹2,535.00₹2,535.00₹2,535.000
₹2,535.00+31.20+1.2%₹2,500.00₹2,535.00₹2,476.10427,905
₹2,503.80-41.20-1.6%₹2,545.00₹2,552.00₹2,455.001,311,278
₹2,545.00+109.40+4.5%₹2,436.80₹2,559.00₹2,436.801,973,968
₹2,435.60-39.30-1.6%₹2,474.90₹2,488.30₹2,430.30388,832
₹2,474.90-25.10-1.0%₹2,488.30₹2,504.60₹2,454.40333,769
₹2,500.00+35.00+1.4%₹2,442.60₹2,504.30₹2,442.60447,288
₹2,465.00-15.00-0.6%₹2,475.10₹2,493.00₹2,458.10352,575
₹2,480.00+42.20+1.7%₹2,450.00₹2,490.00₹2,438.70667,075
₹2,437.80+137.10+6.0%₹2,312.70₹2,452.00₹2,303.001,342,757
₹2,300.70+0.700.0%₹2,300.00₹2,329.50₹2,287.70484,552
₹2,300.00+54.00+2.4%₹2,252.70₹2,308.80₹2,242.10488,064
₹2,246.00-34.50-1.5%₹2,280.50₹2,300.70₹2,246.00650,768
₹2,280.50+0.500.0%₹2,280.00₹2,300.90₹2,251.80446,450
₹2,280.000.000.0%₹2,280.00₹2,280.00₹2,280.000
₹2,280.00+41.60+1.9%₹2,237.20₹2,280.00₹2,222.00530,698
₹2,238.40-26.60-1.2%₹2,260.00₹2,276.50₹2,235.10180,515
₹2,265.00-44.00-1.9%₹2,305.00₹2,317.60₹2,250.00266,219
₹2,309.00-9.00-0.4%₹2,318.00₹2,330.80₹2,301.00186,335
₹2,318.00-9.90-0.4%₹2,317.00₹2,331.60₹2,303.50153,500
₹2,327.90-40.90-1.7%₹2,366.50₹2,390.00₹2,317.00122,389
₹2,368.80-22.70-0.9%₹2,390.00₹2,390.00₹2,355.4098,805
₹2,391.50+35.00+1.5%₹2,351.00₹2,391.50₹2,341.20334,009
₹2,356.50-62.70-2.6%₹2,381.40₹2,381.40₹2,350.00282,979
₹2,419.20+36.30+1.5%₹2,407.60₹2,419.20₹2,343.60391,957
₹2,382.90-34.60-1.4%₹2,419.00₹2,422.10₹2,370.00190,737
₹2,417.50+23.80+1.0%₹2,405.00₹2,417.50₹2,377.60322,167
₹2,393.70+28.70+1.2%₹2,358.00₹2,423.90₹2,358.00513,001
₹2,365.00-9.50-0.4%₹2,374.40₹2,374.40₹2,337.60415,562
₹2,374.50-9.50-0.4%₹2,385.00₹2,385.10₹2,367.10130,471
₹2,384.00-1.000.0%₹2,385.00₹2,407.20₹2,365.60343,261
₹2,385.00-9.00-0.4%₹2,413.00₹2,413.00₹2,373.40307,625
Ticker
NSE:MANKIND
Asset type
Stock
Sector
Health care
Industry
Pharmaceuticals
Exchange
NSE
Currency
INR

What changed lately

Latest news

All Mankind Pharma Ltd. news

Mankind Pharma Ltd. on 6ix

Sector
Health care
Industry
Pharmaceuticals
News releases
7 in the last 12 months · 22 in all · newest Oct 26, 2026 · oldest 2023
Calls
2 calls with a replay · 2 with a transcript · latest Oct 26, 2026
Decks
32 decks · latest Oct 27, 2026

Where Mankind Pharma Ltd. is listed

ListingExchangeCountryCurrency
NSE:MANKIND · Home listing · This pageNSEIndiaINR
BSE:MANKINDBSEIndiaINR

Valuation

P/E 49.1× against a median of 32.9×: 8th lowest of 10 Pharmaceuticals companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
₹1.13T INR
P/E
49.1×
EV/sales
7.3×
EV/EBITDA
27.7×
Price/book
6.3×
Gross margin
58.7%
Operating margin
20.6%
Net margin
14.6%
Debt to equity
0.3×
Beta
No index for this market yet

Pharmaceuticals: the 10 companies nearest in size, of 492 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Mankind Pharma Ltd. · NSE:MANKINDUS$11.88BUS$12.18B49.1×7.3×27.7×6.3×14.6%0.3×n/a
Ipsen SA · EURONEXT:IPNUS$14.62BUS$13.51B30.0×3.4×11.2×2.8×12.1%0.2×n/a
Laurus Labs Ltd. · NSE:LAURUSLABSUS$13.38BUS$13.66B92.5×16.2×53.2×20.5×17.1%0.4×n/a
Zydus Lifesciences Limited · NSE:ZYDUSLIFEUS$12.92BUS$13.86B28.6×4.2×17.9×4.3×13.8%0.5×n/a
Elanco Animal Health Incorporated · NYSE:ELANUS$12.87BUS$15.85Bn/a3.1×13.1×1.9×−2.9%0.5×1.20
Dr. Reddy's Laboratories Ltd. · NSE:DRREDDYUS$12.50BUS$12.45B41.4×3.5×22.6×3.0×8.5%0.2×n/a
Cipla Ltd · NSE:CIPLAUS$12.34BUS$11.26B39.5×3.7×21.6×3.2×10.4%0.0×n/a
Zhangzhou Pientzehuang Pharmaceutical Co., Ltd. Class A · SSE:600436US$11.62BUS$11.29B58.9×9.5×n/a5.5×16.7%0.0×n/a
Aurobindo Pharma Ltd · NSE:AUROPHARMAUS$11.17BUS$11.02B25.9×2.8×13.4×2.6×10.8%0.2×n/a
Lupin Limited · NSE:LUPINUS$9.94BUS$9.65B17.7×2.9×10.1×3.8×17.0%0.2×n/a
Sichuan Kelun Pharmaceutical Co., Ltd. Class A · SZSE:002422US$9.70BUS$8.05B32.9×2.9×n/a2.5×10.7%0.0×n/a
Median of the othersUS$12.42BUS$11.87B32.9×3.4×15.6×3.1×11.5%0.2×1.20

Forecasts

Analysts' consensus from EODHD, read Nov 9, 2026. Not 6ix's view and not investment advice.

Price target
2703.26 INR · Analysts' mean
EPS, year to Mar 2027
58.88 · 17 analysts
Revenue, year to Mar 2027
163.1B · 19 analysts

Team and board

Officers

OfficerRole
Sheetal AroraCEO & Whole-Time Director
Arjun JunejaChief Operating Officer
PK AroraDirector - FHA
Rajeev JunejaVice Chairman & Managing Director
Ramesh JunejaExecutive Chairman

Board

DirectorRole
Ramesh JunejaExecutive Chairman
Anish Vanraj BafnaIndependent Director
Satish Kumar SharmaWhole-Time Director
Sheetal AroraCEO & Whole-Time Director
Tilokchand Punamchand OstwalIndependent Director
Vijaya SampathIndependent Director
Vivek KalraIndependent Director

Events

Next results
Jan 26, 2027 (expected)

Calls

CallWhenStatus
Mankind Pharma (NSE:MANKIND) Q2 2027 Earnings CallMon, Oct 26, 2026 · 10:10 AM ETReplay
Mankind Pharma (NSE:MANKIND) Q1 2027 Earnings CallThu, Jul 30, 2026 · 10:58 AM ETReplay

Results days

QuarterResultsShare move
Q2 2027Oct 26, 2026 · Before open+4.5%
Q1 2027Jul 30, 2026 · Before open−0.7%
Q4 2026May 19, 2026 · Before open−0.1%
Q3 2026Feb 3, 2026 · Before open+4.8%
Q2 2026Nov 6, 2025 · Before open−2.5%
Q4 2025May 21, 2025 · Before open−0.7%
Q3 2025Jan 23, 2025 · Before open+4.7%
Q2 2025Nov 5, 2024 · Before open−0.6%
Q4 2024May 15, 2024 · Before open−2.6%
Q3 2024Jan 31, 2024 · Before open−2.6%
All 12 quarters
QuarterResultsShare move
Q2 2024Oct 31, 2023 · Before open−0.6%
Q1 2024Aug 2, 2023 · Before open−1.8%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (October 2026)Investor deck27 slidesOct 27, 2026
Q2 FY27 Earnings PresentationEarnings26 slidesOct 26, 2026
Q1 FY27 Earnings PresentationEarnings24 slidesJul 30, 2026
Q4 FY26 Earnings PresentationEarnings33 slidesMay 19, 2026
Q3 FY26 Earnings PresentationEarnings31 slidesFeb 3, 2026
Q3 FY26 Earnings PresentationEarnings30 slidesFebruary 2026
Q2 FY26 Earnings PresentationEarnings34 slidesNov 6, 2025
Q2 FY26 Earnings PresentationEarnings33 slidesNovember 2025
Q1 FY2026 Earnings PresentationEarnings30 slidesJul 31, 2025
Q1 FY26 Earnings PresentationEarnings29 slidesJuly 2025
All 32 decks
DeckKindSlidesDate
Q4 FY25 Earnings PresentationEarnings35 slidesMay 21, 2025
Q4 FY25 Earnings PresentationEarnings34 slidesMay 2025
Q3 FY2025 Earnings PresentationEarnings28 slidesJan 23, 2025
Q3 FY25 Earnings PresentationEarnings27 slidesJan 23, 2025
Q2 FY25 Earnings PresentationEarnings30 slidesNov 5, 2024
Investor Presentation (September 2024)Investor deck41 slidesSep 2, 2024
Investor Presentation (September 2024)Investor deck40 slidesSeptember 2024
20th Annual Global Investor Conference organized by Motilal Oswal (August 2024)Conference32 slidesAug 20, 2024
20th Annual Global Investor Conference organized by Motilal Oswal (August 2024)Conference31 slidesAug 1, 2024
Q1 FY25 Earnings PresentationEarnings35 slidesJul 31, 2024
Merger or Acquisition (July 2024)Merger or acquisition22 slidesJul 25, 2024
Merger or Acquisition (July 2024)Merger or acquisition21 slidesJuly 2024
Q4 & FY24 Earnings PresentationEarnings37 slidesMay 15, 2024
Q4 FY24 Earnings PresentationEarnings36 slidesMay 15, 2024
Q3 FY24 Earnings PresentationEarnings33 slidesJan 31, 2024
42nd Annual JP Morgan Healthcare Conference (January 2024)Conference25 slidesJan 10, 2024
JP Morgan Healthcare Conference (January 2024)Conference24 slidesJan 10, 2024
Q2 FY24 Earnings PresentationEarnings31 slidesOct 31, 2023
Q1 FY2024 Earnings PresentationEarnings30 slidesAug 2, 2023
Q1 FY2024 Earnings PresentationEarnings29 slidesAugust 2023
Q4 FY23 Earnings PresentationEarnings25 slidesMay 30, 2023
Q4 FY23 Earnings PresentationEarnings24 slidesMay 2023

Open Decks

Financials

Annual, in INR

Income statement

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Revenue142.8B122.1B102.6B87.5B77.8B62.1B58.7B49.8B
Cost of revenue81.2B35.7B32.6B29.6B24.7B18.2B4.55B17.5B
Gross profit61.6B86.4B70.0B57.9B53.1B43.9B54.1B32.3B
Research and development2.32B254.5M254.5M20.4M123.7M1.10B
Selling, general and administrative15.0B27.2B23.0B11.0B1.25B748.8M529.7M11.1B
Operating income27.3B25.2B22.4B16.4B18.8B16.1B14.7B16.5B
Depreciation and amortization8.86B6.21B3.98B3.26B1.67B1.19B990.6M661.7M
EBITDA36.2B31.4B26.4B19.7B20.5B17.3B15.7B17.1B
Interest expense6.39B4.08B278.2M419.9M202.3M177.2M156.4M
Income before tax23.3B25.2B24.0B16.7B19.7B16.9B14.4B8.75B
Income tax3.95B5.10B4.57B3.62B5.22B3.99B3.82B2.64B
Net income19.1B19.9B19.1B12.8B14.3B12.7B10.3B5.79B
Earnings per share, basic46.2849.2047.6832.0035.7831.5925.7214.44

Balance sheet

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Cash and equivalents4.83B5.54B3.82B3.05B3.03B1.67B2.26B1.16B
Short-term investments15.4B16.9B30.0B12.2B9.77B18.4B8.58B246.2M
Receivables17.3B15.4B8.48B6.06B4.27B4.24B6.26B2.20B
Inventory21.4B20.9B15.5B15.0B17.6B11.8B8.99B8.21B
Current assets69.5B69.9B65.7B43.3B44.1B39.1B28.2B20.0B
Goodwill64.9B64.9B200.2M200.2M204.4M204.4M204.4M204.5M
Total assets280.8B277.6B119.6B97.2B91.5B63.7B50.7B41.1B
Accounts payable13.4B11.3B11.0B7.77B10.8B6.67B7.45B5.62B
Current liabilities65.1B56.6B21.2B18.6B26.2B13.5B12.6B10.2B
Long-term debt28.2B55.3B248.7M231.5M491.9M576.7M503.4M
Total debt63.1B85.1B2.07B1.70B8.73B2.41B1.28B2.70B
Total liabilities115.2B131.9B23.9B20.7B28.3B15.1B14.0B11.3B
Shareholders' equity163.0B143.3B93.6B74.4B61.6B47.2B34.9B28.2B
Shares outstanding413.3M404.7M401.2M400.6M400.6M400.6M400.6M400.6M

Cash flow

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Cash from operations25.2B24.1B21.5B18.1B9.20B11.4B10.7B6.00B
Capital spending-6.26B-4.61B-3.82B-8.32B-23.5B-3.12B-2.28B-2.98B
Free cash flow18.9B19.5B17.7B9.53B-14.3B8.25B8.42B3.03B
Cash from investing-2.54B-126.9B-20.8B-10.5B-13.7B-12.2B-4.39B-4.44B
Cash from financing-22.9B102.3B52.7M-7.40B6.05B-78.1M-5.31B-2.28B
Dividends paid-412.7M-3.64B-240.4M
Change in cash754.1M218.7M771.9M217.6M1.56B-924.0M1.03B-719.9M

Open Financials

Filings

FilingDateTypeFiled with
Mankind Pharma Limited has informed the Exchange regarding a press release dated October 26, 2026, titled "Press Release on Financial Results for Q2 & H1 FY27".Oct 26, 2026ResultsNSE India
Mankind Pharma Limited has informed the Exchange regarding a press release dated October 15, 2026, titled "Press Release titled Mankind Pharma to Acquire Majority Stake in Armed Cell Therapeutics, Marking Strategic Entry into Next-Generation CAR-T Therapies ".Oct 15, 2026Acquisition or disposalNSE India
Mankind Pharma Ltd. Press Release Aug 20 2026Aug 20, 2026Other filingsNSE India
Mankind Pharma Ltd. Press Release Jul 30 2026Jul 30, 2026ResultsNSE India
Press Release May 19 2026May 19, 2026ResultsNSE India
Press Release Mar 18 2026Mar 18, 2026Acquisition or disposalNSE India
Press Release Feb 03 2026Feb 3, 2026ResultsNSE India
Press Release Nov 06 2025Nov 6, 2025ResultsNSE India
Press Release Jul 31 2025Jul 31, 2025ResultsNSE India
Press Release May 21 2025May 21, 2025Other filingsNSE India
All 21 filings
FilingDateTypeFiled with
Press Release Jan 23 2025Jan 23, 2025ResultsNSE India
Press Release Nov 05 2024Nov 5, 2024ResultsNSE India
Press Release Oct 23 2024Oct 23, 2024Acquisition or disposalNSE India
Press Release Jul 31 2024Jul 31, 2024Other filingsNSE India
Press Release Jul 25 2024Jul 25, 2024Acquisition or disposalNSE India
Press Release May 15 2024May 15, 2024ResultsNSE India
Press Release Mar 11 2024Mar 11, 2024Other filingsNSE India
Press Release Jan 31 2024Jan 31, 2024ResultsNSE India
Press Release Oct 31 2023Oct 31, 2023Other filingsNSE India
Press Release Aug 02 2023Aug 2, 2023ResultsNSE India
Press Release May 30 2023May 30, 2023ResultsNSE India

Open Filings

Cap table

Built by 6ix from Mankind Pharma Ltd.’s releases

Common shares
413,045,090
Fully diluted
413,045,090

Fully diluted

LineShares
Common shares413,045,090

Share count over time

CountShares
Nov 22, 2026413,045,090

Open Cap table

Shareholders

HolderSharesValueAs of
Vanguard Total International Stock Index Fund1.66MUS$42.9MJul 31, 2026
Vanguard Emerging Markets Stock Index Fund1.58MUS$40.9MJul 31, 2026
iShares Core MSCI Emerging Markets ETF1.43MUS$35.8MMay 31, 2026
iShares MSCI India ETF604KUS$15.1MMay 31, 2026
iShares MSCI Emerging Markets ex China ETF300KUS$7.51MMay 31, 2026
iShares MSCI Emerging Markets ETF295KUS$7.36MMay 31, 2026
Vanguard Ftse All-World Ex-Us Index Fund261KUS$6.76MJul 31, 2026
Fidelity Series Global ex U.S. Index Fund203KUS$5.25MJul 31, 2026
Franklin FTSE India ETF185KUS$4.98MJun 30, 2026
iShares Core MSCI Total International Stock ETF182KUS$4.7MJul 31, 2026
Show 50 holders
HolderSharesValueAs of
Schwab Emerging Markets Equity ETF136KUS$3.39MMay 31, 2026
Fidelity Emerging Markets Index Fund127KUS$3.28MJul 31, 2026
Greater India Portfolio119KUS$3.21MJun 30, 2026
Vanguard Total World Stock Index Fund91,185US$2.36MJul 31, 2026
Nuveen Emerging Markets Equity Index Fund90,093US$2.33MJul 31, 2026
Avantis Emerging Markets Equity ETF73,638US$1.84MMay 31, 2026
College Retirement Equities Fund - Total Global Stock Account68,288US$1.84MJun 30, 2026
Fidelity Total International Index Fund62,670US$1.62MJul 31, 2026
Dimensional Emerging Markets Core Equity 2 ETF54,873US$1.42MJul 31, 2026
Fidelity Global ex U.S. Index Fund53,774US$1.39MJul 31, 2026
Dimensional Emerging Core Equity Market ETF48,403US$1.25MJul 31, 2026
The Emerging Markets Series46,789US$1.21MJul 31, 2026
WisdomTree India Earnings Fund42,160US$1.13MJun 30, 2026
Columbia EM Core ex-China ETF41,725US$1.12MJun 30, 2026
iShares MSCI ACWI ETF40,677US$1.05MJul 31, 2026
iShares MSCI All Country Asia ex Japan ETF37,507US$971KJul 31, 2026
iShares MSCI ACWI ex U.S. ETF35,258US$912KJul 31, 2026
State Street Global All Cap Equity ex-U.S. Index Portfolio31,924US$859KJun 30, 2026
Fidelity SAI Emerging Markets Index Fund31,115US$805KJul 31, 2026
WisdomTree Emerging Markets ex-State-Owned Enterprises Fund28,827US$775KJun 30, 2026
Emerging Markets Equity Index Fund26,164US$708KJun 30, 2026
College Retirement Equities Fund - Global Equities Account22,343US$601KJun 30, 2026
Vanguard ESG International Stock ETF21,577US$539KMay 31, 2026
Dimensional World ex. U.S. Core Equity 2 ETF20,364US$527KJul 31, 2026
iShares MSCI Emerging Markets Asia ETF17,898US$447KMay 31, 2026
International Strategic Equity Allocation Fund15,614US$396KMay 31, 2026
Emerging Markets Core Equity 2 Portfolio14,061US$364KJul 31, 2026
Six Circles Managed Equity Portfolio International Unconstrained Fund13,484US$364KJun 30, 2026
JNL Emerging Markets Index Fund11,988US$323KJun 30, 2026
Total International Ex U.S. Index Master Portfolio10,660US$287KJun 30, 2026
Avantis Emerging Markets Equity Fund8,430US$211KMay 31, 2026
Emerging Markets ex China Core Equity Portfolio8,093US$210KJul 31, 2026
State Street Emerging Markets Equity Index Fund7,559US$203KJun 30, 2026
JPMorgan BetaBuilders Emerging Markets Equity ETF7,291US$189KJul 31, 2026
World ex U.S. Core Equity Portfolio6,971US$181KJul 31, 2026
Dimensional Emerging Markets Sustainability Core 1 ETF6,308US$163KJul 31, 2026
John Hancock Multifactor Emerging Markets ETF5,601US$151KJun 30, 2026
Voya VACS Index Series EM Portfolio5,503US$148KJun 30, 2026
International Equity Index Trust4,645US$126KJun 30, 2026
Emerging Markets Equity Fund3,608US$91,373May 31, 2026

This page holds 50 of 76 holders. Open Shareholders

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Anish Vanraj BafnaIndependent Director · Since at least Nov 6, 2026
Arjun JunejaChief Operating Officer · Since at least Nov 6, 2026
PK AroraDirector - FHA · Since at least Nov 6, 2026
Rajeev JunejaVice Chairman & Managing Director · Since at least Nov 4, 2026
Ramesh JunejaExecutive Chairman · Since at least Nov 4, 2026
Satish Kumar SharmaWhole-Time Director · Since at least Nov 6, 2026
Sheetal AroraCEO & Whole-Time Director · Since at least Nov 4, 2026
Tilokchand Punamchand OstwalIndependent Director · Since at least Nov 6, 2026
Vijaya SampathIndependent Director · Since at least Nov 6, 2026
Vivek KalraIndependent Director · Since at least Nov 6, 2026

Open People

Log in to ask 6ix AI your own questions about Mankind Pharma Ltd.